KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Amortization of Deferred Charges (2020 - 2025)

Esperion Therapeutics (ESPR) has disclosed Amortization of Deferred Charges for 6 consecutive years, with $641000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization of Deferred Charges changed N/A year-over-year to $641000.0, compared with a TTM value of $19.5 million through Dec 2025, changed N/A, and an annual FY2025 reading of $3.0 million, changed N/A over the prior year.
  • Amortization of Deferred Charges was $641000.0 for Q4 2025 at Esperion Therapeutics, down from $9.1 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $9.1 million in Q2 2025 and bottomed at -$1.3 million in Q4 2023.
  • Average Amortization of Deferred Charges over 5 years is $1.2 million, with a median of $414000.0 recorded in 2022.
  • The sharpest move saw Amortization of Deferred Charges tumbled 405.8% in 2023, then soared 1958.82% in 2025.
  • Year by year, Amortization of Deferred Charges stood at $407000.0 in 2021, then grew by 1.72% to $414000.0 in 2022, then crashed by 405.8% to -$1.3 million in 2023, then soared by 30.57% to -$879000.0 in 2024, then soared by 172.92% to $641000.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for ESPR at $641000.0 in Q4 2025, $9.1 million in Q3 2025, and $9.1 million in Q2 2025.